Drug Profile

Catequentinib - Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical

Alternative Names: AL-3818; ALTN; Anlotinib; Anlotinib hydrochloride; Anrotinib; FOCUS V

Latest Information Update: 20 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Advenchen Laboratories; Jiangsu Chia-Tai Tianqing Pharmaceutical
Developer Advenchen Laboratories; Akeso Biopharma; Chia Tai Tianqing Pharmaceutical Group; Henan Cancer Hospital; Peking University People's Hospital
Class Amines; Antineoplastics; Cyclopropanes; Ethers; Fluorinated hydrocarbons; Indoles; Quinolines; Small molecules
Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ovarian cancer; Soft tissue sarcoma
New Molecular Entity Yes

Marketed Medullary thyroid cancer; Non-small cell lung cancer; Small cell lung cancer; Soft tissue sarcoma; Thyroid cancer
Preregistration Endometrial cancer
Phase III Alveolar soft part sarcoma; Colorectal cancer; Gastric cancer; Leiomyosarcoma; Liver cancer; Nasopharyngeal cancer; Synovial sarcoma
Phase II Bone cancer; Cancer; Cervical cancer; Cholangiocarcinoma; Ewing's sarcoma; Fallopian tube cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
Phase I/II Acral lentiginous melanoma
No development reported Solid tumours

31 May 2024 Efficacy and adverse events data from the phase II ALTER-G-001 trial in Gastrointestinal cancer presented at the 60^th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
31 May 2024 Safety and efficacy data from a phase II trial in Squamous cell cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
17 May 2024 Launched for Small cell lung cancer (Second-line therapy or greater) in China (PO) prior to May 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com